UDCA API Manufacturer Audit: 10-Point Due Diligence Checklist

Auditing a ursodeoxycholic acid (UDCA) API manufacturer before committing to a purchase order is not optional — it is the single most important step in pharmaceutical procurement. A poorly vetted supplier can cost months of regulatory delays, rejected shipments at customs, or worse: a product recall. This article provides a 10-point checklist that QA managers and procurement teams can use to verify a UDCA API manufacturer's quality, compliance, and reliability before signing a supply agreement.

1. Why Audit a UDCA API Manufacturer?

UDCA is a high-value bile acid API with strict pharmacopoeia requirements. The price gap between EP-grade (with CEP) and non-pharmacopoeia grade material can exceed 40%, creating incentives for misrepresentation. Common problems found during audits include:

• CoA manipulation: Batch CoAs that do not match retained sample test results when independently verified
• CDCA carryover: Incomplete epimerization leaving chenodeoxycholic acid above EP limits (0.10%) but claimed as compliant
• GMP on paper only: Facilities that hold a GMP certificate but have not passed a competent authority inspection in over three years
• Brokered material: Supplier reselling UDCA purchased from a third-party manufacturer without disclosing the original source

A structured audit catches these issues before they become your problem. The checklist below covers every stage from desktop document review to on-site factory inspection.

2. The 10-Point Due Diligence Checklist

3. CoA Deep Dive: What the Numbers Mean

The Certificate of Analysis is the most frequently falsified document in API procurement. Here is how to read a UDCA CoA correctly:

3.1 Assay (HPLC Purity)

A UDCA CoA reporting "≥ 99.0%" without specifying the analytical method is incomplete. The pharmacopoeia standard is HPLC on the anhydrous basis. USP allows 98.0-102.0%, while EP requires 99.0-101.0% — a narrower and tighter window. If a supplier claims EP-grade but the CoA shows assay at the low end (98.5-99.0%), ask why.

3.2 Water Content (Loss on Drying)

UDCA is hygroscopic. Water content directly affects the assay value reported on the anhydrous basis. A CoA with assay 99.5% but no water content value is meaningless — the reported purity may be inflated by not correcting for moisture. Both USP and EP require loss on drying ≤ 1.0%.

3.3 Key Solvent: Ethanol

Ethanol is the most common residual solvent in synthetic UDCA because it is used in the final crystallization step. The EP monograph explicitly limits ethanol to ≤ 5,000 ppm. USP references ICH Q3C, which classifies ethanol as a Class 3 solvent (low toxicity) with a recommended limit of 5,000 ppm. A CoA showing ethanol at 8,000-10,000 ppm suggests the crystallization solvent was not adequately removed.

3.4 Related Substances: The Three You Must Check

Impurity	EP Limit	Why It Matters
Chenodeoxycholic acid (CDCA)	≤ 0.10%	Process impurity — incomplete epimerization. CDCA is the 7α-epimer precursor; its presence indicates poor synthesis control
Lithocholic acid	≤ 0.15%	Degradation product with known hepatotoxicity. Levels above 0.15% are a safety concern and a quality system failure
Any other individual impurity	≤ 0.10%	Unidentified peaks on the HPLC chromatogram should each be below 0.10%. Multiple peaks near 0.10% suggest an uncontrolled process

Total impurities per EP must not exceed 0.5%. USP allows up to 2.0% total impurities — this is one reason EP-grade UDCA commands a significant price premium.

4. Impurity Profile Red Flags

When reviewing the related substances section of a UDCA CoA, watch for these specific warning signs:

• Missing impurity data: A CoA that reports "conforms" for related substances without listing individual impurity values. This is not acceptable for pharmaceutical-grade material. Request the full HPLC chromatogram with peak identification.
• CDCA near the limit: CDCA at 0.09-0.10% meets the EP specification but indicates the epimerization process is operating at its boundary. Batch-to-batch consistency at this level is unlikely.
• Unidentified peaks: Any peak > 0.05% that the manufacturer cannot identify by retention time or mass spectrometry. These may be process-related impurities from a non-standard synthetic route.
• Column overload: If the CoA HPLC chromatogram shows a flat-topped main peak, the column was overloaded and impurity peaks may be under-reported. Request a re-analysis at standard loading.

5. On-Site Factory Audit Protocol

Desktop document review identifies about 70% of supplier quality issues. The remaining 30% require a physical factory visit. Here is a focused audit agenda for a one-day UDCA API supplier visit:

Time	Activity	Key Observations
09:00-10:00	Opening meeting + quality system overview	Organizational structure, QA independence from production, CAPA system maturity
10:00-11:30	Production walk-through	Equipment cleanliness, material flow (cholic acid → epimerization → purification → final crystallization), batch records on the shop floor
11:30-12:30	QC laboratory tour	HPLC instrument calibration logs, column inventory (correct columns for UDCA analysis), reference standard management (USP/EP standards)
13:30-14:30	Warehouse & sampling	Raw material receipt and quarantine procedures, sampling booth design, retained sample program (3+ years of samples)
14:30-15:30	Documentation review	3 recent batch records (complete, not summary), deviation reports, OOS investigation files, stability study protocols
15:30-16:00	Closing meeting	Summary of findings, preliminary audit outcome, corrective action timeline

Three questions that reveal more than any checklist: (1) "Can you show me your last three out-of-specification investigations?" (2) "When was your last regulatory inspection, and what observations did you receive?" (3) "What happens to batches that fail release testing?" A supplier who answers these questions transparently passes the most important test.

6. Eight Deal-Breaker Red Flags

Any one of these findings should stop a procurement decision until resolved:

1. CoA without batch number or date — a template, not a real test result
2. CEP status shows "suspended" or "withdrawn" on the EDQM database
3. GMP certificate expired or issued by an unrecognized body
4. Manufacturing site address mismatch between CoA, GMP certificate, and CEP/DMF
5. Refusal to provide HPLC chromatogram — secrecy around analytical data
6. No retained sample program — cannot verify past batch quality
7. CDCA consistently at 0.09-0.10% — process operating at specification limit
8. Pricing significantly below market — genuine EP-grade UDCA has a production cost floor

7. Frequently Asked Questions

UDCA Content Cluster

References

• ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
• ICH Q3C: Guideline for Residual Solvents
• ICH Q1A: Stability Testing of New Drug Substances and Products
• European Pharmacopoeia Monograph 01/2024:1275 — Ursodeoxycholic Acid
• USP Monograph: Ursodiol
• EDQM Certification Database
• PIC/S PI 023-2: Guidance on Good Practices for Aseptic Preparation
• EU GMP Part II: Basic Requirements for Active Substances used as Starting Materials